Phaseline

Companies › Neuvosyn Laboratories

Neuvosyn Laboratories: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
North Star Desiccated Porcine Thyroid Extract Tablets
Desiccated porcine thyroid extract (contains T3 and T4 hormones)
–Phase 3HypothyroidismNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07747103North Star Desiccated Porcine Thyroid Extract TabletsPhase 3HypothyroidismMetabolic and endocrineNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.